Dexcom falls after FDA's warning letter over deficiencies at two facilities

Shares of medical device maker Dexcom DXCM.O fall 6.2% to $73 in extended trade

Co says it had received a warning letter from the U.S. FDA following inspections of its two key manufacturing facilities

The warning letter contains observations and identified issues in manufacturing processes and quality management system at DXCM's facilities in San Diego, California and Mesa, Arizona

Co does not expect a material impact from the letter to its manufacturing capacity or its sales outlook for fiscal year 2025

DXCM fell 37.3% in 2024